CHINARES PHARMA (03320.HK): Unit completes 2026 bond issue at 1.48%
- The Company's announcement on the first tranche of its 2026 corporate bonds was dated 16 April 2026.
- The net proceeds will be used for repayment of corporate debts, replenishment of working capital, project development and operating expenses, technological innovation investments and other purposes permitted by applicable laws and regulations.
NewTimeSpace News: On 16 October 2026, China Resources Pharmaceutical Group Limited (stock code: 03320) announced that China Resources Pharmaceutical Holdings Company Limited, its wholly-owned subsidiary, has completed the public issue of the second tranche of its 2026 corporate bonds in the PRC, with a principal amount of RMB 900 million, a term of three years and a coupon rate of 1.48% per annum.
The net proceeds will be used for productive expenditure, including repayment of corporate debts, replenishment of working capital, project development and operating expenses, investments relating to technological innovation and other purposes in compliance with applicable laws and regulations. The announcement was made pursuant to Rule 13.09 of the Listing Rules and the inside information provisions under Part XIVA of the Securities and Futures Ordinance.
- CHINARES PHARMA (03320.HK): Pre-bid process starts on unit share issue
- CHINARES PHARMA(03320.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 2.19 billion, YoY increase of 5.26%
- CHINARES PHARMA (03320.HK)：Issues 1.4 Billion Yuan 3-Year Corporate Bonds with 1.65% Coupon Rate
- China Resources Pharmaceutical Group Limited (03320.HK): Plans to Acquire 23.50% Equity Stake in Lier Chemical at Consideration of Approximately RMB 5.656 Billion
